TY - GEN
T1 - Intravascular Sonothrombolysis, in vitro, Using a Small Aperture, Forward-Viewing, Sub-Megahertz Transducer to Enhance tPA Treatment
AU - Goel, Leela
AU - Wu, Huaiyu
AU - Kim, Howuk
AU - Zhang, Bohua
AU - Kim, Jinwook
AU - Dayton, Paul
AU - Xu, Zhen
AU - Jiang, Xiaoning
N1 - Publisher Copyright:
© 2019 IEEE.
PY - 2019/10
Y1 - 2019/10
N2 - Catheter-based thrombolytic treatments with tissue plasminogen activator (tPA) have long treatment times (>15 hrs) and high risk of intracranial hemorrhage. Sonothrombolysis may improve patient outcomes while reducing the dose of tPA needed for treatment. We recently demonstrated a custom, forward-viewing intravascular (FVI) transducer with microbubbles (MBs) for in vitro sonothrombolysis. For clinical translation, we want to utilize this transducer to enhance tPA treatment. Therefore, the purpose of this study was to examine the thrombolytic outcomes of a forward-looking, IV transducer with tPA in vitro. Blood clots were treated for 30 minutes with either phosphate buffer saline (PBS), ultrasound (US) alone, tPA alone (1μg/ml), tPA + US, or MB + US (108 MB/ml). The percent clot lysis for the control group was 29 ± 4%, tPA alone was 29 ± 9%, and US alone was 25 ± 4%, with no statistically significant differences amongst these conditions. The percent clot lysis was 58 ± 10%, 59 ± 3% and 63 ± 5% for tPA + US and MB + US conditions respectively and both had statistically significantly more clot lysis than the control, US alone, or tPA alone groups. We have demonstrated that a forward-viewing intravascular transducer can be used to enhance tPA mediated sonothrombolysis and is comparable to microbubble mediated sonothrombolysis.
AB - Catheter-based thrombolytic treatments with tissue plasminogen activator (tPA) have long treatment times (>15 hrs) and high risk of intracranial hemorrhage. Sonothrombolysis may improve patient outcomes while reducing the dose of tPA needed for treatment. We recently demonstrated a custom, forward-viewing intravascular (FVI) transducer with microbubbles (MBs) for in vitro sonothrombolysis. For clinical translation, we want to utilize this transducer to enhance tPA treatment. Therefore, the purpose of this study was to examine the thrombolytic outcomes of a forward-looking, IV transducer with tPA in vitro. Blood clots were treated for 30 minutes with either phosphate buffer saline (PBS), ultrasound (US) alone, tPA alone (1μg/ml), tPA + US, or MB + US (108 MB/ml). The percent clot lysis for the control group was 29 ± 4%, tPA alone was 29 ± 9%, and US alone was 25 ± 4%, with no statistically significant differences amongst these conditions. The percent clot lysis was 58 ± 10%, 59 ± 3% and 63 ± 5% for tPA + US and MB + US conditions respectively and both had statistically significantly more clot lysis than the control, US alone, or tPA alone groups. We have demonstrated that a forward-viewing intravascular transducer can be used to enhance tPA mediated sonothrombolysis and is comparable to microbubble mediated sonothrombolysis.
KW - clot lysis
KW - intravascular sonothrombolysis
KW - sonothrombolysis
UR - http://www.scopus.com/inward/record.url?scp=85077636041&partnerID=8YFLogxK
U2 - 10.1109/ULTSYM.2019.8926028
DO - 10.1109/ULTSYM.2019.8926028
M3 - Conference contribution
AN - SCOPUS:85077636041
T3 - IEEE International Ultrasonics Symposium, IUS
SP - 2034
EP - 2036
BT - 2019 IEEE International Ultrasonics Symposium, IUS 2019
PB - IEEE Computer Society
T2 - 2019 IEEE International Ultrasonics Symposium, IUS 2019
Y2 - 6 October 2019 through 9 October 2019
ER -